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Abstract
It has been difficult to measure efficacy of T cell-based vaccines and to correlate efficacy of
CD8+T cell responses with protection against viral infections. In part, this difficulty is due
to our poor understanding of the in vivo efficacy of CD8+T cells. Using a recently developed
experimental method of in vivo cytotoxicity we investigated quantitative aspects of killing
of peptide-pulsed targets by effector and memory CD8+T cells, specific to three epitopes of
lymphocytic choriomeningitis virus (LCMV), in the mouse spleen. By analyzing data on killing
of targets with varying number of epitope-specific effector and memory CD8+T cells, we find
that killing of targets by effectors follows the law of mass-action, that is the death rate of
peptide-pulsed targets is proportional to the frequency of CTLs in the spleen. In contrast,
killing of targets by memory CD8+T cells does not follow the mass action law because the
death rate of targets saturates at high frequencies of memory CD8+T cells. For both effector
and memory cells, we also find no support for a killing term that includes the decrease of the
death rate of targets with increasing target cell density. Importantly, we find that at low CD8+T
cell frequencies, effector and memory CD8+T cells on the per capita basis are equally efficient
at killing peptide-pulsed targets. Our framework provides the guideline for the calculation
of the level of memory CD8+T cells required to provide sterilizing protection against viral
infection. Our results thus form a basis for quantitative understanding of the process of killing
of virus-infected cells by T cell responses in tissues and can be used to correlate the phenotype
of vaccine-induced memory CD8 T cells with their killing efficacy in vivo .
Short running title: Killing by CD8+T cells in tissues
Abbreviations: LCMV, lymphocytic choriomeningitis virus, CTLs, cytotoxic T lympho-
cytes, CIs, confidence intervals, RSS, residual sum of squares
1 Introduction
Vaccination is often considered as one of the greatest medical achievements of the last century
but due our limited understanding of the correlates of protection, most vaccines have been
developed by a trial and error approach and we have failed to deliver vaccines for important
diseases like AIDS or malaria. It is generally believed that most of the currently used vaccines
provide protection by inducing high titers of pathogen-neutralizing antibodies (1). The efficacy
of an antibody-inducing vaccine is generally proportional to the titer of neutralizing antibodies
after vaccination (2). Several vaccines that are currently being developed for chronic infections
such as HIV and malaria, are aimed to stimulate T cell responses. It is unclear, however, what
parameters of the T cell memory that is induced by vaccination, best correlate with protection
(1). It has been suggested that polyfunctional memory CD4 T cells may be superior in providing
protection following infection with Leishmania (3) and polyfunctional memory CD8+T cells are
protective against SIV infection (4), but for some important human infections, such as HIV
infection, evidence is still lacking (5, 6).
In part, our limited understanding of how memory T cells provide protection comes from
the fact that most effector functions of effector and memory T cells are measured in vitro
(after short- or long-term restimulation), and there is very little quantitative details of how T
cells control pathogen growth in tissues (e.g., (7)). Recently, a new experimental technique to
measure cytotoxic efficacy of CD8+T cells in vivo has been introduced (8, 9, 10, 11, 12). In this
assay, peptide-pulsed and unpulsed target cells are transferred into mice harboring peptide-
specific effector or memory CD8+T cells, and elimination of pulsed targets is used as indication
of Ag-specific killing in vivo (13, 14, 15, 16, 17). We use the data from recently published
experiments (14) and use a recently developed mathematical model (18, 19, 20) to investigate
quantitative details how of effector and memory CD8+T cells, specific for three epitopes of
lymphocytic choriomeningitis virus (LCMV), kill peptide-pulsed targets in the mouse spleen.
Unexpectedly, our results suggest that killing of targets by effector CD8+T cells (present at
the peak of the immune response) follows the law of mass action: the rate of killing is simply
proportional to the density of targets and the frequency of effector CD8+T cells in the spleen.
Such a linear dependence of the death rate of targets on the frequency of effectors was observed
over 100 fold range of effector frequencies. In contrast, killing of targets by LCMV-specific
memory CD8+T cells does not follow the law of mass action as the death rate of peptide-
pulsed targets saturates at high frequencies of memory CD8 T cells. This saturation suggests
that there might be an upper bound level of efficacy of the total memory T cell response,
and this may potentially limit the efficacy of T-cell based vaccines. Interestingly, we found
that at low CD8+T cell frequencies, effector and memory CD8+T cells are equally efficient
at clearing peptide-pulsed targets. This suggests that T-cell based vaccines would provide
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sterilizing immunity if memory CD8+T cells, that are generated by vaccination, were to remain
present at high enough frequencies (21, 22).
This analysis may form a basis for quantitative understanding of efficacy of T cell-based
vaccines. By correlating expression of various cell surface and intracellular markers with the
in vivo killing efficacy of memory T cells of different specificities in mice, we may better un-
derstand which qualities of memory cells provide best protection. For example, one could ask
if polyfunctional CD8+T cell induced by vaccination are better killers in vivo than monofunc-
tional memory T cells (23). Such information can potentially be further used to predict efficacy
of T cell-based vaccines in humans.
2 Material and Methods
2.1 Cytotoxicity in vivo
Experimental method of measuring cytotoxicity of CD8+ T cells in vivo has been describes
in great detail elsewhere (e.g., (17)). In this report, we analyze recently published data on
killing of peptide-pulsed splenocytes by LCMV-specific effector and memory CD8+ T cells (14,
& see Figure 1). The reader is referred to the original publication for more detail. In the first
set of experiments (“in vivo LCMV infection”), target splenocytes were pulsed with NP396 or
GP276 peptides of LCMV (10 µM) or left unpulsed. Targets were subsequently transferred
into syngenic mice either infected with LCMV 8 days previously (“acutely infected” mice)
or recovered from LCMV infection (LCMV-immune or “memory” mice). At different times
after the transfer, spleens were harvested, and the number of pulsed and unpulsed targets,
splenocytes, and peptide-specific CD8+T cells was calculated.
In the second set of experiments (“adoptive transfer”), 106 of P14 CD8+T cells, expressing
a TCR specific for the GP33 epitope of LCMV, were adoptively transferred into recipient B6
mice which were then infected i.p. with LCMV-Arm (24). Eight (for effectors) or 40 (for
memory T cells) days later, different numbers of P14 CD8+T cells harvested from these mice
were transferred into new naive recipients (Figure 1B). The number of effector CD8+T cells
transferred into different recipients was 106, 2× 106, 107, and 2× 107. The number of memory
CD8+T cells transferred into different recipients was 106, 2 × 106, and 107. Two hours later,
two populations of CFSE labeled splenocytes, one of which was pulsed with the GP33 peptide
of LCMV (1 µM), were transferred into these recipient mice, harboring the transferred GP33-
specific effector or memory CD8+T cells. Percent targets killed was calculated at different times
after target cell transfer as described earlier (14, 17). The ratio of the frequency of pulsed to
unpulsed targets, used in fitting of the data, was calculated as R = 1 − L/100 where L is the
percent of peptide-pulsed targets killed (17, 18).
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Figure 1: Schematic representation of the in vivo cytotoxicity assays undertaken to investigate the
quantitative details of CD8+T cell mediated killing of peptide-pulsed targets in the mouse spleen. In
the first set of experiments (“LCMV infection”, panel A), B6 mice were infected with LCMV-Arm and
8 or 37-100 days later, three populations of 5 × 106 target cells (pulsed with either NP296 or GP276
peptides of LCMV and unpulsed) were transferred into these mice. In the second set of experiments
(“adoptive transfer”, panel B), P14 TCR Tg CD8+T cells, specific to the GP33 epitope of LCMV,
were transferred into B6 mice and then infected with LCMV-Arm. Eight or 40 days later, different
number of effector (day 8) or memory (day 40) P14 CD8+T cells from these mice were transferred
into new naive B6 mice. In panel B, we shown an example of 2×106 effectors or memory CD8+T cells
transferred. Two hours later, two populations of 5 × 106 targets (pulsed with the GP33 peptide of
LCMV and unpulsed) were transferred into these mice now harboring GP33-specific CD8+T cells. In
both sets of experiments, killing of peptide-pulsed targets was measured in spleens of mice at different
times after cell transfer (14).
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2.2 Mathematical model for the cytotoxicity in vivo assay
Details of the mathematical model proposed to describe migration of injected targets from
the blood to the spleen and killing of peptide-pulsed targets in the spleen are given in great
detail elsewhere (18, see also Supplementary Information). In short, target cells injected i.v.
migrate from the blood to the spleen at a rate σ, die at a rate ǫ due to preparation techniques
(independent of CD8+T cell mediated killing), or migrate to other tissues and/or die elsewhere
at a rate δ. In the spleen, targets die due to preparation-induced death rate ǫ, and peptide-
pulsed targets also die due to CD8+T cell mediated killing, described by the rate K. The
dynamics of unpulsed targets S(t) and the ratio of the frequency of peptide-pulsed to unpulsed
targets R(t) in the spleen is given by equations (18)
S(t) =
SB(0)σ
d− ǫ
[
1− e−(d−ǫ)t
]
e−ǫt, (1)
R(t) =
(d− ǫ)
(K − (d− ǫ))
[
e−(d−ǫ)t − e−Kt
1− e−(d−ǫ)t
]
e−ǫt, (2)
where d = σ + ǫ + δ is the rate of removal of cells from the blood and SB(0) = 5 × 10
6 is the
initial number of unpulsed targets in the blood (14).
We have shown previously that the rate of recruitment of target cells from the blood to the
spleen depends on the spleen size (18). Therefore, to describe recruitment of targets into the
spleen we let the rate of recruitment be σ = α×Nsi where Nsi is the number of splenocytes in
the ith mouse and α is a coefficient (18).
In our previous study we estimated the death rate of targets K, pulsed with NP396 or
GP275 peptides of LCMV, due to killing by the total effector or memory CD8+T cell response
(18). To estimate the per capita killing efficacy of CD8+T cells, we have to relate the death
rate of peptide pulsed targets K to the density of epitope-specific CD8+T cells in the mouse
spleen. It is generally assumed that killing of targets follows the law of mass action, that is
the death rate of peptide-pulsed targets is proportional to the frequency of peptide-specific
CD8+T cells (19, 20). However, spleen tissue has a complicated structure and the assumption
of mass-action like encounter of targets and CD8+T cells need not hold. Therefore, here we test
several different killing terms in how well they describe the data from the in vivo cytotoxicity
assay. In a mass-action model, killing occurs at a rate that is proportional to the frequency of
targets and the frequency of epitope-specific CD8+T cells Ei in the spleen of the i
th mouse, i.e.,
the death rate of peptide-pulsed targets in the ith mouse due to CD8+T cell mediated killing is
K = kEi (3)
Alternatively, it is possible that the encounter rate between targets and killers does not
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follow the law of mass-action and is affected by the frequency or the number of CD8+T cells
and/or the number of frequency of targets. For example, the death rate of peptide-pulsed
targets may saturate with increasing killer frequencies of decrease with increasing target cell
frequencies (see Supplementary Information for more detail).
To fit the data on recruitment of targets into the spleen and on killing of peptide-pulsed
targets in the spleen at the same time we log-transform the data and the model predictions.
To access lack of fit of the data with repeated measurements we use the F-test (25, p. 29). To
compare nested models we also use the F-test (25, p. 104). Fittings were done in Mathematica
5.2 using the routine FindMinimum.
3 Results
3.1 Killing efficacy of T cells following acute LCMV infection
To investigate quantitative aspects of how effector and memory CD8+T cells kill their targets
in a mouse spleen we analyze data from recently published experiments on killing of targets
pulsed with either NP396, GP276, or GP33 peptides from LCMV by peptide-specific effector or
memory CD8+T cells (14). Mice, infected with LCMV-Armstrong develop a vigorous CD8+T
cell response that peaks 8 days after the infection (26, 27). By 15-30 days after the infection,
most of effectors die and a population of LCMV-specific memory CD8+T cells persists for the
life of the animal (27). To measure the efficacy of effector and memory CD8+T cells, target cells
pulsed with LCMV-specific peptides (NP396 or GP276) were transferred into mice infected 8 or
37− 100 days previously (14), and the percent of targets killed by effectors or memory CD8+T
cells was calculated (see Materials and Methods and Figure 1).
We have previously developed a mathematical model to estimate the killing efficacy of
LCMV-specific T cell responses from the data obtained in such in vivo cytotoxicity assay (18).
The model describes the most important processes: recruitment of target cells from the blood
to the spleen, death of targets due to preparation, and killing of peptide-pulsed targets by
the total peptide-specific CD8+T cell response in the spleen (18, see Materials and Methods).
From these data we estimated the death rate of peptide-pulsed targets due to killing by the
total effector or memory CD8+T cell response (18).
Here we extend this model by allowing different terms for the killing of targets by epitope-
specific CD8+T cells (see Materials and Methods). Using the approach of a previous study (19),
we first fitted the data from acutely infected and LCMV-immune mice assuming that killing of
targets is proportional to the frequency of epitope-specific CD8+T cells in the spleen of a given
mouse. Although this model fits the data, the quality of the fit to the data was rather poor
(lack of fit test: F30,158 = 3.1, p = 2.6× 10
−6). Assuming that the death rate of peptide-pulsed
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targets K is dependent on the total number of epitope-specific CD8+T cells, rather than their
frequency, led to even worse fits of the data (lack of fit test: F30,158 = 5.54, p = 3.4 × 10
−13).
The reason for the poor fit is that the frequency (or total number) of epitope-specific CD8+T
cells measured in an individual mouse predicted poorly killing of targets in the same mouse
(Figure S1 in Supplementary Information).
We therefore explored several modifications of the model to improve the fit of the model to
the data (see Supplementary Information). The best description of the data was obtained by
assuming that killing of targets is determined by the average frequency of NP396- and GP276-
specific effector or memory CD8+T cells in the spleen and not values measured in individual
mice (lack of fit test: F30,162 = 0.79, p = 0.77; see Table 1 and Figure S2 in Supplementary
Information). The good fit of this model to data suggests that variation in the frequency of
epitope-specific CD8+T cells measured in different mice is largely due to measurement noise.
The absence of a positive correlation between the number of targets killed and the CD8+T
cell frequency in a given mouse further supports this conclusion (Figure S3). This analysis
suggested that LCMV-specific CD8+T cells are half as efficient as are effector CD8+T cells of
the same specificity (Table 1).
Another version of the model in which the death rate of targets due to CD8+T cell killing
saturates with increasing T cell frequency (see eqn. (A.10) in Supplementary Information)
significantly improved the fit of the model to data (F-test for nested models: F1,186 = 50.3,
p = 2.7 × 10−11). This model predicted that memory CD8+T cells are 10 fold less efficient
killers than effector T cells of the same specificity (see Supplemental Information). It should
be noted, however, that if measurements of CD8+T cell frequencies in individual mice are
noisy, saturation in killing with T cell frequency is expected to be important since it allows for
smoothing of noisy data.
3.2 Killing efficacy of T cells following adoptive transfer of T cells
Thus, we generated two alternative models that provided a good description of the data but
generated highly distinct predictions on the efficiency and nature of killing of targets in the
mouse spleen. To discriminate between these alternative models we analyzed novel data from
additional experiments involving transfer of different numbers of effector or memory CD8+T
cells specific to the GP33 epitope of LCMV (14, see Figure 1B). Two hours after transfer
of CD8+T cells, GP33-pulsed and unpulsed target cells were transferred into mice harboring
GP33-specific CD8+T cells, and killing of peptide-pulsed targets was measured longitudinally
(14, Figure 2). Approximately 2 to 10% of the adoptively transferred CD8+T cells accumulated
in the mouse spleen (Table 2). Since the transfer of different numbers of epitope-specific CD8+T
cells led to different frequencies of these cells in the spleen as well as to different effector to
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Parameter Mean 95% CIs E/T E, % E, 106 cells cell type
αA, 10
−12 min−1 7.17 5.63 − 9.25
αM , 10
−11 min−1 1.30 0.90 − 1.88
ǫ, 10−3 min−1 4.71 3.37 − 6.12
γ 0.49 0.35 − 0.66
kNP396, min
−1 5.50 4.26 − 7.21 2471 6.3 10.4 NP396-spec effectors
kGP276, min
−1 2.35 1.85 − 2.89 130 2.1 3.6 GP276-spec effectors
γkNP396, min
−1 2.68 2.10 − 3.32 4.9 0.54 0.32 NP396-spec memory
γkGP276, min
−1 1.14 0.79 − 1.54 1.5 0.35 0.21 GP276-spec memory
Table 1: Parameters providing the best fit of the mathematical model assuming that the rate of
recruitment of targets into the spleen depends on the spleen size and that killing of peptide-pulsed
targets depends on the average frequency of epitope-specific CD8+T cells in the spleen. Here αA and
αM are coefficients relating the recruitment rate of cells into the spleen σ = αNsi in acutely infected
(αA) and memory (αM ) mice, and Nsi is the number of splenocytes in individual mice, γ is the ratio
of the killing efficacy of epitope-specific memory CD8+T cells to that of effector CD8+T cells, kNP396
and kGP276 are the per capita killing efficacy of NP396- and GP276-specific effector CD8
+T cells, and
γkNP396 and γkGP276 are the killing efficacy of NP396- and GP276-specific memory CD8
+T cells,
respectively. In the fits the rate of migration of labeled splenocytes to other organs δ was fixed to 0
since this did not affect the quality of the model fit to data (F-test for nested models: F1,191 = 0.15,
p = 0.70). Data and model fits are shown in Figure S2. CIs were calculated by bootstrapping the
data with 1000 simulations (28). Note that the fits predict that epitope-specific memory CD8+T cells
on the per capita basis are half as efficient as effectors (γ = γNP396 = γGP276 ≈ 0.5; F-test for nested
models: F1,191 = 0.03, p = 0.88). For different experiments, we also show the average effector to target
ratio (E/T ), the average percentage, and the average total number of epitope-specific CD8+T in the
spleen obtained from the data.
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target ratios (Table 2), these data allowed for a unique opportunity to investigate whether the
per capita killing efficacy of LCMV-specific effector and memory CD8+T cells is independent
of these two quantities.
Therefore, we fitted the mathematical model given in eqn. (1)-(2) to these data assuming
that the death rate of peptide-pulsed targets K depends on the average frequency of GP33-
specific CD8+T cells in the spleen (i.e., killing follows the law of mass action). The model
described the data very well with the exception of one time point with very few unpulsed
targets being recruited into the spleen (Figure 2A at 2 × 107 effector CD8+T cell transferred;
lack of fit test with this time point removed: F20,50 = 0.92, p = 0.56). By fitting the model, we
estimated parameters determining the rate of migration of targets from the blood to the spleen
as well as the per capita killing efficacy of GP33-specific effector (given by ki) and memory
(given γi × ki) CD8
+T cells, at different frequencies of effectors of memory CD8+T cells in
the spleen (Table 2 and Figure 3). Surprisingly, the model fits predicted that the per capita
killing efficacy of effector CD8+T cells was largely independent of the frequency of effectors
in the spleen equaling on average kGP33 = 2.1 ± 0.17 min
−1. Most importantly, this estimate
is almost identical to the estimate of the killing efficacy of GP276-specific effectors obtained
above by fitting the data from acute LCMV infection using the average frequency of epitope-
specific CD8+T cells in the spleen (see Table 1). Thus, this analysis suggests that changing
the frequency of epitope-specific CD8+T cells in the mouse spleen from 6 × 10−4 (transfer of
106 GP33-specific effectors, see Table 2) to 2 × 10−2 (GP276-) or 6 × 10−2 (NP396-specific
effectors, see Table 1) does not affect the per capita killing efficacy of LCMV-specific effector
CD8+T cells. In other words, this implies that killing of targets in the mouse spleen by effector
CD8+T cells follows the law of mass action where the rate of killing is proportional to the
frequency of epitope-specific CD8+T cells. This conclusion was further confirmed by the lack
of improvement of the data fit with the model assuming saturation in the death rate of peptide-
pulsed targets with CTL frequency (F-test for nested models: F1,16 = 0.62, p = 0.44). Thus,
for LCMV-specific effectors, the correct model is the one in which killing of targets is simply
proportional to the average frequency of CTLs in the spleen.
In contrast with effectors, we estimated that the per capita killing efficacy of memory
CD8+T cells declines with an increasing number of memory T cell transferred (Table 2 and
Figure 3). The killing efficacy of memory CD8+T cells was somewhat higher than that of
effectors at the lowest number of epitope-specific CD8+T cell transferred, and lower when
larger numbers of memory T cells were transferred (Figure 3). This suggests that the death
rate of peptide-pulsed targets due to killing by memory CD8+T cells saturates as the function
of the frequency of CD8+T cells (or the effector to target ratio) in the mouse spleen. Including
saturation in the death rate of targets with memory CD8+T cell frequency (see eqn. (A.10))
significantly improved the quality of the model fit to data on killing of peptide-pulsed targets
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by NP396- and GP276-specific memory CD8+T cells (F-test for nested models: F1,78 = 15.3,
p = 2.0 × 10−4). These fits also predicted that at low T cell frequencies, memory T cells
are at least as efficient as effectors of the same specificity (for memory CD8+T cells assuming
saturation in killing: kNP396 = 6.2 min
−1, kGP276 = 2.2 min
−1, cE = 302.4; compare these
estimates to the killing efficacy of effectors given in Table 1), confirming the result from the
adoptive transfer experiment. Moreover, the estimated saturation constant cE implies that
killing efficacy of memory T cells is reduced by half at the cell frequency equal 1/cE ≈ 0.35%
which is again observed in both following LCMV infection (Table 1) and after adoptive transfer
of GP33-specific memory T cells (Table 2). Thus, these results suggest that the death rate of
peptide-pulsed targets saturates with increasing the frequency of memory CD8+T cells in the
mouse spleen.
Assuming that the death rate of peptide-pulsed targets is proportional to the total number
of epitope-specific CD8+T cells in the mouse spleen, we found that following acute LCMV
infection effector and memory CD8+T cells have a similar per capita killing efficacy (results
not shown). This is contrast to the result obtained from the adoptive transfer experiments where
at frequencies of epitope-specific effector and memory CD8+T cells in the spleen of ∼ 0.35%,
memory T cells are only 30% to 50% as efficient as effectors. This suggests that killing targets
in the spleen is proportional to the frequency, and not the total number of epitope-specific
CD8+T cells confirming a previously made assumption (19, 20).
4 Discussion
Recent interest in T cell based vaccines against several chronic infections of humans requires
the development of experimental and theoretical tools to access the efficacy of such vaccines
(29, 30). It is generally believed that memory CD8+T cells induced by vaccination are not
able to provide sterilizing immunity, because T cells react only to infected cells, i.e., after
the infection has been established. However, a recent study has shown an example where
generation of a large population of memory CD8+T cells by vaccination in mice did provide
sterilizing immunity against malaria (21).
Quantitative approaches aimed at estimating the in vivo efficacy of effector and memory
CD8+T cells, and at quantitative details of how CD8+T cells control growth of pathogens
are necessary to understand how protection induced by T cell-based vaccines is achieved. This
study utilized a recently developed experimental technique of in vivo cytotoxicity to investigate
how effector and memory CD8+T cells, specific to LCMV, kill peptide-pulsed targets in the
mouse spleen. Using a novel mathematical model we have analyzed data from experiments on
in vivo killing of targets following LCMV infection of mice and experiments involving adoptive
transfer of different numbers of LCMV-specific effector or memory CD8+T cells. Results of our
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Figure 2: Fits of the mathematical model to data from experiments involving adoptive transfer of
different numbers of epitope-specific effector (panels A&C) or memory (panels B&D) CD8+T cells.
Panels A and B show the number of unpulsed targets in the spleen at different times after cell transfer.
Panels C and D show the change in the ratio of the frequency of peptide-pulsed to unpulsed targets
in the spleen with time. Different symbols denote data from different adoptive transfer experiments
with 106, 2 × 106, 107, or 2 × 107 T cells transferred. Symbols denote individual measurements with
averages per time point being connected by solid lines. Brown symbols are the model predictions with
averages being connected by dashed lines. Parameters providing the best fits of the model are shown
in Table 2. Note that in panel A, the model does not predict the decline in the number of unpulsed
targets with time in experiments with transfer of 2× 107 GP33-specific effectors. Such decline in the
number of unpulsed targets in the spleen is unexpected and is most likely due to a measurement error.
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Parameter Mean 95% CIs E/T E, % E, 106 cells Cells transferred
α, 10−11 min−1 cell−1 2.14 1.88–6.16
ǫ, 10−3 min−1 1.1 0.4–1.6
δ, 10−2 min−1 1.0 0.7–4.3
k1, min
−1 1.77 0.91–2.12 0.14 0.06 0.05
106
γ1k1, min
−1 3.26 2.54–3.83 0.09 0.04 0.03
k2, min
−1 1.77 0.91–2.12 0.34 0.18 0.10
2× 106
γ2k2, min
−1 0.98 0.54–1.22 0.25 0.15 0.09
k3, min
−1 3.08 1.6–3.9 23.7 0.87 0.68
107
γ3k3, min
−1 0.93 0.61–1.07 9.48 1.25 1.05
k4, min
−1 1.77 0.91–2.12 44.4 1.54 1.43 2× 107
Table 2: Estimates of parameters of the mathematical model fitted to the data from the adoptive
transfer experiments. In different experiments, 106, 2×106, 107 or 2×107 effector or memory CD8+T
cells were transferred resulting in the shown average effector to target ratio E/T , average percentage or
the total number of transferred cells in the recipient mice. We estimated the killing efficacy of effectors
(ki) and the ratio of the killing efficacy of an effector to that of a memory cell (γi) by assuming that
the death rate of peptide pulsed targets is proportional to the frequency of epitope-specific CD8+T
cells in the spleen, K = kE where k and γk is the killing efficacy of GP33-specific effector and memory
CD8+T cells, respectively. Killing efficacies k1, k2 and k4 were fitted as one parameter since this did
not significantly affect the quality of the model fit to data (F2,68 = 2.84, p = 0.07). Further reduction
of the number of model parameters resulted in the significantly worse description of the data (results
not shown). Interestingly, this data also lead to a non-zero estimate of the preparation-induced cell
death rate that we have previously postulated to exist (18), although in these experiments this rate
was smaller than during acute LCMV infection (see Table 1).
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Figure 3: Estimated per capita killing efficacy of GP33-specific effector CD8+T cells (A) and the
ratio of killing efficacy of GP33-specific memory to that of effector CD8+T cells (B) as the function
of the number of transferred effectors or memory cells. Error bars show the 95% confidence intervals
for estimated parameters. These results suggest that there is a minimal change in the per capita
killing efficacy of GP33-specific effector CD8+T cells with effector T cell frequency (with an average
of kGP33 = 2.1 ± 0.17 min
−1) but that the efficacy of memory CD8 T cells declines at high numbers
of transferred cells.
analysis suggest that death rate of targets due to LCMV-specific effectors is simply proportional
to the average frequency of epitope-specific CD8+T cells in the mouse spleen. This is a rather
surprising result. Even for frequencies of LCMV-specific effectors in the spleen ranging over 100
fold from 0.06% to 6%, we find no evidence in saturation in the death rate of peptide-pulsed
targets with CD8+T cell frequency. This in turn suggests that killing of targets by CTLs follows
the law of mass action (31) and that CTLs do not compete for access to targets at least when
their frequency in the spleen is as high as 6%.
We found that killing of targets is dependent on the frequency of epitope-specific CD8+T
cells in the spleen and not their total number. This has important implications for vaccination
since this suggests that inducing high numbers of virus-specific CD8+T cells may not be highly
advantageous if their frequency in tissues is low. The observation that the death rate of peptide-
pulsed targets is mainly determined by the average frequency of epitope-specific CTLs suggests
that a large variation in the frequency of CD8+T cells in the spleen, as measured in individual
mice, represents measurement noise.
We found that at low CD8+T cell frequencies, memory CD8+T cells are at least as efficient at
killing peptide-pulsed targets as are effector CD8+T cells. This contradicts the widely accepted
view that memory CD8+T cells, especially those residing in lymphoid tissues, are not very
efficient killers and generally require restimulation to exhibit cytotoxicity (32). Our study as
well as the original work of Barber et al. (14) illustrates the limitation of the in vitro chromium
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release assay to assess cytotoxic efficacy of memory CD8+T cells.
We also found that at high frequencies (e.g., following acute LCMV infection), LCMV-
specific memory T cells are only half as efficient as are effector CD8+T cells of the same
specificity. The reduction in the killing efficacy of memory CD8+T cells with increasing their
frequency may limit the overall efficacy of T cell-based vaccines, since boosting the frequency
of memory T cells may not lead to a proportional increase in the efficacy of the memory T cell
response. Different efficacies of effector and memory CD8+T cells following LCMV infection
may be due to different localization of these two subsets in the spleen. A recent study suggests
that LCMV-specific effectors localize mainly in the red pulp, while memory CD8+T cells reside
in the T cell zones of the white pulp of the mouse spleen (33). Since white pulp occupies the
minority of the space in the spleen (5-20%, (34)), memory CD8+T cells indeed are expected to
compete for the access to targets if their density in the white pulp is high. However, additional
studies addressing the question of localization of target cells in the mouse spleen are needed to
investigate this issue further.
We found that NP396-specific effector CD8+T cells present at the peak of the immune
response have a per capita killing efficacy kNP396 = 5.5 min
−1. This value has a simple inter-
pretation as the death rate of targets when the frequency of CTLs in the spleen is close to 1. For
example, if most of splenocytes were NP396-specific CD8+T cells, NP396-pulsed targets would
have a half-life of ln 2/5.5 = 7.5 seconds in the spleen. Another interesting parameter that can
be calculated from our study is the number of targets killed by one CTL per unit of time. In
an extreme situation where all splenocytes are targets for a single CTL a NP396-specific CTL
is expected to kill kNP396×1/Ns×Ns = kNP396 ≈ 5 targets per minute (or 7.2×10
3 targets per
day). In our experiments, the number of targets was generally much smaller than the number
of splenocytes, and since the number of targets killed per day per CTL depends on the number
of targets, we previously estimated that following LCMV infection, CTLs kill only a few targets
per day at these high effector to target ratios (18).
The time taken by a CTL to kill its target is a sum of the time required by a CTL to
find its target and the time to deliver the lethal hit. By assuming that the rate of killing of
peptide-pulsed targets is limited mainly by the time required by an effector T cell to find its
target, we calculated an approximate upper bound estimate for the killing efficacy of T cells.
Given the estimated motility of activated T cells in lymph nodes and the size of targets, the
maximum killing efficacy of CD8+T cells is k ≈ 72 min−1, although this value does depend on
the several parameters that have not been measured in our experiments (see Supplementary
Information). Since the estimated killing efficacy of effector T cells is much lower than this
value, our result suggests that the main limiting step of killing of peptide-pulsed targets is the
actual process of killing, and not finding the target. This is consistent with a recent study on
imaging of killing of B cells by effector CD8+T cells where the process of killing of targets took
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10 to 20 minutes (7). The observation that killing efficacy of effector CD8+T cells is the same
at low and high effector frequencies in the spleen also suggests that finding the target is not
the limiting step in the killing process.
Effector CD8+T cells, specific to two other epitopes of LCMV, are estimated to have a
lower killing efficacy (kGP276 = 2.4 min
−1, kGP33 = 2.1 min
−1). Since we do not expect these
cells to behave differently from NP396-specific effectors, a lower killing efficacy of GP276- and
GP33-specific CD8+T cells is likely because of longer times required by effectors to kill their
targets. This may arise because of the reduced affinity of T cell receptors, specific to these
peptides, to their ligands or a shorter half-life time of peptide-MHC complexes on target cells.
Reduced killing efficacy of memory CD8+T cells as compared to effectors of the same speci-
ficity is expected as memory T cells generally express low levels of molecules such as perforin,
granzymes, and FasL that are required for mediating cytotoxicity (14). Even though memory
CD8+T cells may have a reduced motility in lymphoid tissues as compared to activated, ef-
fector T cells, this is an unlikely reason for their reduced killing efficacy. We have found that
at low T cell frequencies GP33-specific memory CD8 T cells are at least as efficient killers as
are effectors. This may imply that high levels of granzymes and perforin that are expressed by
effector CD8+T cells are not required for high degree of cytotoxicity in vivo .
Our results have important implication for the loss of protection by memory CD8+T cells.
It has been suggested that infection with new pathogens leads to attrition (loss) of memory
CD8+T cells specific to previously encountered pathogens (35, 36, 37, 38). A recent study has
challenged this conclusion by showing that infection of mice with Vesicular stomatitis virus
(VSV) and Vaccinia virus (VV) can also lead to an increase in the total number of memory T
cells, and as the result, to a very moderate loss of the total number of memory CD8+T cells,
specific to previously encountered virus (LCMV), in the spleen (39). However, this study has
also shown a dramatic reduction in the frequency of LCMV-specific memory CD8+T cells in the
spleen and in peripheral tissues following infection with VSV and VV. Our results suggest that
reduction in the frequency of virus-specific memory CD8+T cells may have a dramatic affect
on the efficacy of the memory response even if the total number of virus-specific CD8+T cells
is not dramatically reduced. Reduction in the cytotoxic efficacy of Vaccinia virus- or Pichindie
virus-specific memory CD8+T cell responses has indeed been observed after exposure to LCMV
(38, 40).
Our results suggest a simple procedure of estimating the frequency of memory CD8+T cells
at which T cells may provide sterilizing immunity upon re-exposure to a virus. From a simple
equation governing the growth of the virus V ′(t) = (r− kE
1+cEE
)V (t), this frequency of memory
CD8+T cells is given by the ratio E = r
k−rcE
where r is the rate of replication of the virus,
k is the killing efficacy of memory CD8+T cells, and cE is the half-saturation constant. For
a virus such as LCMV that doubles its population size in ln 2/5 = 3.4 hours (41, 42, 43), the
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protective frequency of memory CD8+T cells which have a killing efficacy k = 2.5 min−1 is
5/(2.5 − 300 × 5) ≈ 0.24% of all splenocytes. This is below the level of memory CD8+T cells
induced by vaccination with LCMV-Armstrong (see Table 1), suggesting that LCMV-immune
mice should be protected following infection with other strains of LCMV even in the absence
of LCMV-specific antibodies. Future studies will be necessary to address this quantitative
prediction.
Our study may provide practical guidelines for estimating the efficacy of T cell based vac-
cines. It has been recently shown that cytotoxic potential of HIV-specific CD8+T cells may
be one of the most important components of effective control of viral growth (44). Because of
practical difficulties in performing in vivo cytotoxicity assay in humans, it would be interesting
to correlate the in vivo killing efficacy of murine CD8+T cells with their phenotype measured
ex vivo by flow cytometry (e.g., cell surface and intra-cellular markers). This may allow for
quantitative understanding of what constitutes an effective memory T cell; this understanding
can be further applied to compare efficacy of T cell-based vaccines in humans.
In our analysis, we used the ratio of the frequency of peptide-pulsed to unpulsed targets as a
measure of killing. It has been shown previously that the ratio is indeed a less biased estimator
than, for example, the frequency of peptide-pulsed targets in the spleen (20). The use of the
ratio, however, precludes the analysis of whether killing of targets depends on the total number
of targets or their frequency in the spleen. Addressing this question will be explored elsewhere.
We have investigated quantitative aspects of killing of peptide-pulsed targets in the spleen.
It would be important to investigate if killing of virally infected cells and/or targets in other
organs such as the lung or the gut follows the same principle. Including these processes may
require the use of more sophisticated mathematical models, and as such will hopefully lead to
more collaborations between experimentalists and theoreticians.
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List of Figures
1 Schematic representation of the in vivo cytotoxicity assays undertaken to inves-
tigate the quantitative details of CD8+T cell mediated killing of peptide-pulsed
targets in the mouse spleen. In the first set of experiments (“LCMV infection”,
panel A), B6 mice were infected with LCMV-Arm and 8 or 37-100 days later,
three populations of 5 × 106 target cells (pulsed with either NP296 or GP276
peptides of LCMV and unpulsed) were transferred into these mice. In the second
set of experiments (“adoptive transfer”, panel B), P14 TCR Tg CD8+T cells,
specific to the GP33 epitope of LCMV, were transferred into B6 mice and then
infected with LCMV-Arm. Eight or 40 days later, different number of effector
(day 8) or memory (day 40) P14 CD8+T cells from these mice were transferred
into new naive B6 mice. In panel B, we shown an example of 2×106 effectors or
memory CD8+T cells transferred. Two hours later, two populations of 5 × 106
targets (pulsed with the GP33 peptide of LCMV and unpulsed) were transferred
into these mice now harboring GP33-specific CD8+T cells. In both sets of ex-
periments, killing of peptide-pulsed targets was measured in spleens of mice at
different times after cell transfer (14). . . . . . . . . . . . . . . . . . . . . . . . 3
2 Fits of the mathematical model to data from experiments involving adoptive
transfer of different numbers of epitope-specific effector (panels A&C) or memory
(panels B&D) CD8+T cells. Panels A and B show the number of unpulsed targets
in the spleen at different times after cell transfer. Panels C and D show the
change in the ratio of the frequency of peptide-pulsed to unpulsed targets in the
spleen with time. Different symbols denote data from different adoptive transfer
experiments with 106, 2×106, 107, or 2×107 T cells transferred. Symbols denote
individual measurements with averages per time point being connected by solid
lines. Brown symbols are the model predictions with averages being connected
by dashed lines. Parameters providing the best fits of the model are shown in
Table 2. Note that in panel A, the model does not predict the decline in the
number of unpulsed targets with time in experiments with transfer of 2 × 107
GP33-specific effectors. Such decline in the number of unpulsed targets in the
spleen is unexpected and is most likely due to a measurement error. . . . . . . 10
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3 Estimated per capita killing efficacy of GP33-specific effector CD8+T cells (A)
and the ratio of killing efficacy of GP33-specific memory to that of effector
CD8+T cells (B) as the function of the number of transferred effectors or memory
cells. Error bars show the 95% confidence intervals for estimated parameters.
These results suggest that there is a minimal change in the per capita killing ef-
ficacy of GP33-specific effector CD8+T cells with effector T cell frequency (with
an average of kGP33 = 2.1 ± 0.17 min
−1) but that the efficacy of memory CD8
T cells declines at high numbers of transferred cells. . . . . . . . . . . . . . . . 12
S1 Poor prediction of the model taking into account individual variation in the
measured frequency of epitope-specific effector and memory CD8+T cells. We fit
the model, that predicts that mice with more epitope-specific CD8+T cells should
lead to higher killing, to the data. Here we plot the log ratio of the frequency
of peptide-pulsed to unpulsed target cells that is observed in the data versus
the log ratio that is predicted by the best fit of the model, for different times
after transfer of target cells. Lines show linear regressions. If the model were to
predict the data, the points are expected to lie on a line with a positive slope.
Instead, we observe a large scatter, and for many data, a negative correlation
between the observation and the prediction. . . . . . . . . . . . . . . . . . . . . 31
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S2 Fits of the mathematical model given in eqn. (1)–(2) to data on killing of NP396-
and GP276-pulsed targets by effector and memory CD8+T cells. The model
assumes that the rate of recruitment of targets into the spleen depends on the
spleen size and that killing of peptide-pulsed targets depends on the average
frequency of epitope-specific CD8+T cells. Panels A-B show the recruitment of
unpulsed targets into the spleen, and panels C-F show the decline in the the ratio
of the frequency of peptide-pulsed to unpulsed targets over time. Panels A, C,
and E are for acutely infected mice, and panels B, D, F are for LCMV-immune
(memory) mice. Panels C and D are for NP396-pulsed targets and panels E
and F are the GP276-pulsed targets. Black dots (•) denote measurements from
individual mice, and black lines denote the log average value per time point.
Red boxes (✷) show the number of recruited cells predicted by the model for
individual mice (panels A and B) or the predicted average ratio R (panels C-F).
Red lines show the log average between individually predicted values. Note the
different scale for killing of target cells in acutely infected (panels C and E) and
memory (panels D and F) mice. Parameters providing the best fit of the model
are shown in Table 1. The lack of fit test confirms good quality fits of the data
(after removing two outliers, F30,162 = 0.79, p = 0.77). Because of the reduced
number of parameters, these fits of the data are only moderately worse than
those obtained in our previous study (18). . . . . . . . . . . . . . . . . . . . . . 32
S3 The absence of a strong correlation between the ratio of the frequency of peptide-
pulsed to unpulsed targets at different time points after target cell transfer
(shown in minutes) and the percent of epitope-specific CD8+T cells in the mouse
spleen in acutely infected (panels A and C) and LCMV-immune (panels B and
D) mice. To visualize the data, we use different scales on the plots. If CD8+T
cells were to affect the frequency of peptide-pulsed targets, a negative correlation
between the ratio R and CD8+T cells would be expected. However, especially
in acutely infected mice (panels A and C), there often are positive correlations
between this ratio and the frequency of peptide-specific CD8+T cells. . . . . . . 33
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S4 Changes in the ratio of the frequency of peptide-pulsed to unpulsed targets in
the mouse spleen as predicted by the mathematical model (given in eqn. (1)-
(2)) with different killing terms (given in eqn. (A.10) – (A.13)). The death
rate of peptide-pulsed targets saturates with the frequency of peptide-specific
CD8+T cells (panel A), decreases with the frequency of target cells (panel B) or
saturates on the effector to target ratio (panel C). We solve the mathematical
model analytically (panel A) or numerically (panels B-C) with the following
parameters: SB(0) = TB(0) = 5 × 10
6, S(0) = T (0) = 0, δ = 0.001 min−1,
σ = 0.001 min−1, ǫ = 0.005 min−1, k = 5 min−1, E = 0.05 (see also Table
1). The frequency of targets in the spleen is calculated as T = T (t)/Ns where
Ns = 8 × 10
7 is the number of splenocytes. In all panels, solid lines (with
cE = cT = 0) predict changes in the ratio R if killing follows the law of mass-
action, i.e., K = kE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
S5 Changes in the ratio of the frequency of peptide-pulsed to unpulsed targets in
the mouse spleen as predicted by the mathematical model (given in eqn. (2))
for different frequencies of GP33-specific effectors in the spleen (shown as f).
The death rate of peptide-pulsed targets K is proportional to the frequency of
GP33-specific CD8+T cells, K = kf , with k = 2.1 min−1 as estimated from the
adoptive transfer experiments. Other parameters are α = 2.07 × 10−11 min−1,
Ns = 7.7 × 10
8, ǫ = 1.15 × 10−3 min−1, and δ = 10−2 min−1. There is a small
difference in the percent targets killed between 106 and 2×106 (and between 107
and 2× 107) effectors transferred. . . . . . . . . . . . . . . . . . . . . . . . . . 35
S6 The observed correlation between the ratio of the frequency of GP33-pulsed and
unpulsed targets and the frequency of GP33-specific CD8+T cells in the spleen
at different time points after transfer in the adoptive transfer experiments. Data
are structured by the time since the transfer of target cells (shown in hours).
Lines show linear regressions. Note that there is a relatively small variation in
th measured frequency of epitope-specific CD8+T cells. . . . . . . . . . . . . . 36
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5 Supplementary Information
5.1 Mathematical model for estimating the killing efficacy of CD8+T
cell responses
The dynamics of unpulsed and peptide-pulsed targets in the blood and in the spleen are given
by equations
dSB(t)
dt
= −(δ + σ + ǫ)SB(t), (A.1)
dS(t)
dt
= σSB(t)− ǫS(t), (A.2)
dTB(t)
dt
= −(δ + σ + ǫ)TB(t), (A.3)
dT (t)
dt
= σTB(t)− ǫT (t)−KT (t), (A.4)
where SB(t) and TB(t) are the numbers of unpulsed and peptide-pulsed target cells in the
blood, respectively, and S(t) and T (t) is the number of unpulsed and pulsed targets in the
spleen, respectively, σ is the rate of migration of target cells from the blood into the spleen,
and δ is the rate of cell migration/death from blood to other organs, ǫ is the extra death rate
of transferred splenocytes due to preparation (independent of epitope-specific CD8+T cells),
and K is the death rate of peptide-pulsed targets due to CD8+T cell mediated killing in the
spleen. For our experiments, the initial conditions for the model are SB(0) = TB(0) = 5 × 10
6
cells and S(0) = T (0) = 0 (14). In the case when all model parameters, including the death
rate of targets due to CD8+T cell mediated killing, are independent of time, the model can be
solved analytically (18); and the particular solution for K = const is shown in eqn. (1) and (2).
5.2 Deriving the general killing term
In tissues, CD8+T cells scan many cells to find virus-infected targets, and many of the cells
scanned are uninfected (7). Scanning uninfected cells also takes some time (7), and if the
majority of cells in a tissue is uninfected, a CD8+T cell can spend a substantial amount of time
“looking” for the infected targets. The process of scanning of uninfected targets and killing
peptide-expressing targets can described mathematically to enzyme kinetics (e.g., (45)). We let
E, S, and T be the number of killer CD8+T cells, uninfected (bystander) and peptide-expressing
targets, respectively. Effector CD8+T cells by scanning uninfected targets form a complex C1,
and form a complex C2 when they scan infected cells. Both complexes can dissociate. The
kinetic diagram of cell interactions is then (46)
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E + T
k1
⇋
k
−1
C1
k2
→ E +D, (A.5)
E + S
k1
⇋
k
−2
C2, (A.6)
where k1 and k−1 are the rates for binding and dissociation of a killer T cell and peptide-
expressing cell; k−2 is the dissociation rate of a complex of a killer T cell and a bystander
(uninfected) cell; k2 is the dissociation rate of the complex of killer T cell and an infected cell
resulting in the death of the infected cell (denoted as D). The rate of removal of pulsed targets
is then simply k2C1. Making a quasi-steady state assumption for C1 and C2, we obtain
C1 =
k1
k2 + k−1
TE = K1TE, (A.7)
C2 =
k1
k−2
SE = K2SE. (A.8)
where K1 = k1/(k−1 + k2) and K2 = k1/k−2. If the number of killers E is much larger than
the number of target T (i.e., Eˆ = E + C1 + C2 ≈ E, where Eˆ is the total number of killer T
cells), then rewriting eqn. (A.7) and (A.8) in terms of the total number of unpulsed and pulsed
targets, Sˆ = S +C2, and Tˆ = T +C1, respectively, after simple algebra for the complex C1 we
find
C1 =
K1E
1 +K1E
Tˆ , (A.9)
This suggests that the death rate of peptide-pulsed targets, k2C1/Tˆ , saturates at high
numbers of killer CD8+T cells approaching the rate of dissociation of the complex k2. Then
the death rate of targets is given by
K =
kE
1 + cEE
, (A.10)
where cE is the inverse frequency of CD8
+T cells at which killing is half maximal.
Similarly, if the number of pulsed targets T is much larger than the number of killers
E, then rewriting eqn. (A.7) and (A.8) in terms of the total number of killer CD8+T cells,
Eˆ = E + C1 + C2, we find
C1 =
K1Eˆ
1 +K1T +K2S
T, (A.11)
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where K1 and K2 are defined above. This expression shows that 1) the death rate of peptide-
pulsed targets, k2C1/T , may decrease at high numbers of targets, and 2) if the number of
bystander (unpulsed) targets is high, K2S ≫ K1T , the killing of targets depends on the fre-
quency of effectors in the spleen, Eˆ/S, and not on their absolute number. Simplifying eqn.
(A.11) by letting K2 → 0 we obtain
K =
kE
1 + cTT
, (A.12)
where cT is the inverse frequency of pulsed targets at which killing is half maximal.
Finally, the death rate of a single target may depend on the effector to target ratio, E/T
(47). Then assuming saturation in the death rate with the ratio of effectors to targets, we
obtain
K =
k(E/T )
cT + (E/T )
=
kE
E + cTT
. (A.13)
Note that in those cases, when the death rate of targets due to CD8+T cell mediated killing
K depends on the target cell density (K = K(T ), see eqn. (A.12) and (A.13)), eqn. (2) is not
the correct solution. Instead, we numerically solve the model given by differential equations
(see Supplementary Information) and fit the numerical solution of the model to data.
5.3 Deriving the killing rate constant
Based on the assumption that the speed of a chemical reaction may be limited by rate at
which chemicals are colliding, it has been derived from basic physical principles how the rate
of reaction depends on the properties of interacting chemicals (31). Similar approaches have
been applied in biology to model infection of target cells by a virus (48, 49). Bearing on these
studies, killing of peptide-pulsed target cells T by peptide-specific CD8+T cells E can described
by a simple diagram
E + T
kD
→ D + E, (A.14)
with the kinetics of target cells T given simply as
dT
dt
= −kDTE. (A.15)
Note that in eqn. (A.15), T and E are given as cell concentrations in the spleen (i.e., number
of cells per unit of volume). From a fundamental result of Smoluchowski (31), the rate of the
reaction kD is given by
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kD = 4π(DE +DT )(RE +RT ), (A.16)
whereDE andDT are the diffusion (or motility) coefficients of effectors and targets, respectively,
and RE and RT are radii of the cells. The rate kD needs to be converted to be comparable with
the killing efficacy k that we have estimated from the data (see Table 1 and 2). Because in eqn.
(A.15), concentration of effectors E is given as cells/volume, converting the cell concentration
to the frequency of cells in the spleen yields
k =
kDNs
V
, (A.17)
where Ns is the number of splenocytes and V is the volume of the spleen. Since spleen is packed
mainly with lymphocytes, the simplest assumption is that the spleen volume can be calculated
as vNs where v is the average volume of a splenocyte given by a sphere with the radius RS.
Then
k =
4π(DE +DT )(RE +RT )
v
=
3(DE +DT )(RE +RT )
R3S
. (A.18)
since volume of a splenocyte is simply v = 4/3πR3S. Motility (diffusion) coefficients of T cells in
lymph nodes have been estimated in several studies employing in vivo two photon microscopy
(50, 51). Depending on type of cells, presence of the antigen and activation status of cells, the
motility coefficient has been estimated to range from 10 to 100 µm2/min (51, 52). The average
size of a mouse lymphocyte is about 7 − 10 µm (53). Assuming that motility of activated
effectors is higher than that of targets, we let DE = 100 µm
2/min and DT = 10 µm
2/min.
Given that targets used in our experiments are splenocytes, we also let RT = RS = 4 µm, and
for effectors RE = 10 µm. Then the diffusion limited estimate for the killing efficacy of CD8
+T
cells in vivo is given by
k =
3(100 + 10)(10 + 4)
43
= 72.2 min−1. (A.19)
However, many of the parameter values are unknown for LCMV-specific CD8+T cells, and
changes in these values can affect the estimate of the killing efficacy k dramatically. For example,
if motility coefficient for effector T cells DE = 10 µm/min, then k = 13.1 min
−1 which is still
several fold higher than the value in eqn. (A.19).
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5.4 Alternative ways of fitting the data on killing following in vivo
infection
It is generally unknown what killing terms one should use to describe the process of killing
of targets by effector and memory CD8+T cells. Assuming that killing of targets in a given
mouse is determined the frequency of epitope-specific CD8+T cells in that mouse led to a poor
description of the data (see Main text). Therefore, we investigated whether using different
killing terms can improve the model fit to data.
Including a decrease in the death rate of targets with an increasing frequency of targets (see
eqn. (A.12)) failed to improve the quality of the model fit to data (F-test for nested models,
F1,187 = 0.001, p = 0.98). This was not surprising since this change in the killing term predicts
an increased rate of loss of peptide-pulsed targets with time as more targets are killed, but the
opposite trend is observed in the data (e.g., Figure S2C and Figure S4).
We tested whether the average frequency of epitope-specific CD8+T cells in all mice, rather
than values measured in individual mice, would be predictive of the rate of killing of peptide-
pulsed targets. Therefore, we fitted the data on killing of peptide-pulsed targets using the
mass-action type term K = kE where E is the average frequency of epitope-specific CD8+T
cells in acutely infected or LCMV-immune mice. This resulted in a significantly better fit with
reasonably small confidence intervals for the estimates of the model parameters (lack of fit test:
F30,162 = 0.79, p = 0.77; see also Figure S2).
We allowed the death rate of peptide-pulsed targets due to CD8+T cell mediated killing to
saturate with the measured frequency of epitope-specific CD8+T cells (see eqn. (A.10)). This
also led to a significantly improved fit of the data (F-test for nested models: F1,186 = 50.3,
p = 2.7 × 10−11). The fit predicted very high maximal killing efficacy of effector CD8+T cells
(kNP396 = 146 min
−1, kGP276 = 22 min
−1, cE = 400.4; compare these estimates to values
for effectors given in Table 1). Moreover, this model predicted that memory CD8+T cells are
only 6% (NP396) or 14% (GP276) as efficient as effectors. Such an improvement of the fit by
including saturation of the death rate of peptide-pulsed targets with CTL frequency is expected
if measurements of the frequency of epitope-specific CD8+T cells are noisy.
Finally, by allowing the death rate of peptide-pulsed targets to depend on the ratio of the
frequency of killers to targets (see eqn. (A.13)) we could also obtain an improved fit of the
model to data (lack of fit test: F28,158 = 1.38, p = 0.11). Interestingly, we found a relatively
small estimate for the parameter cT (cT = 1.37). Because effector to target ratios are rather
high in most mice (e.g., E/τ ≈ 103 for NP396- and E/τ ≈ 102 for GP276-specific effectors
and epitope-expressing targets, see Table 1), a small estimate for the constant cT suggests that
the death rate of peptide-pulsed targets saturates with the frequency of CD8+T cells (compare
eqn. (A.13) for E ≫ cTT and eqn. (A.10) for cEE ≫ 1). Therefore, the last two models appear
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to be similar with respect to these in vivo data since both models require saturation in the
death rate of peptide-pulsed targets with the frequency of epitope-specific CD8+T cells for a
satisfactory description of the data. Such a saturation can simply result from the reduction
of the influence of variation of the measured frequency of epitope-specific effector and memory
CD8+T cells on the death rate of peptide-pulsed targets.
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Figure S1: Poor prediction of the model taking into account individual variation in the measured
frequency of epitope-specific effector and memory CD8+T cells. We fit the model, that predicts that
mice with more epitope-specific CD8+T cells should lead to higher killing, to the data. Here we plot
the log ratio of the frequency of peptide-pulsed to unpulsed target cells that is observed in the data
versus the log ratio that is predicted by the best fit of the model, for different times after transfer
of target cells. Lines show linear regressions. If the model were to predict the data, the points are
expected to lie on a line with a positive slope. Instead, we observe a large scatter, and for many data,
a negative correlation between the observation and the prediction.
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Figure S2: Fits of the mathematical model given in eqn. (1)–(2) to data on killing of NP396- and
GP276-pulsed targets by effector and memory CD8+T cells. The model assumes that the rate of
recruitment of targets into the spleen depends on the spleen size and that killing of peptide-pulsed
targets depends on the average frequency of epitope-specific CD8+T cells. Panels A-B show the
recruitment of unpulsed targets into the spleen, and panels C-F show the decline in the the ratio of
the frequency of peptide-pulsed to unpulsed targets over time. Panels A, C, and E are for acutely
infected mice, and panels B, D, F are for LCMV-immune (memory) mice. Panels C and D are
for NP396-pulsed targets and panels E and F are the GP276-pulsed targets. Black dots (•) denote
measurements from individual mice, and black lines denote the log average value per time point. Red
boxes (✷) show the number of recruited cells predicted by the model for individual mice (panels A and
B) or the predicted average ratio R (panels C-F). Red lines show the log average between individually
predicted values. Note the different scale for killing of target cells in acutely infected (panels C and
E) and memory (panels D and F) mice. Parameters providing the best fit of the model are shown
in Table 1. The lack of fit test confirms good quality fits of the data (after removing two outliers,
F30,162 = 0.79, p = 0.77). Because of the reduced number of parameters, these fits of the data are
only moderately worse than those obtained in our previous study (18).
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Figure S3: The absence of a strong correlation between the ratio of the frequency of peptide-pulsed
to unpulsed targets at different time points after target cell transfer (shown in minutes) and the
percent of epitope-specific CD8+T cells in the mouse spleen in acutely infected (panels A and C) and
LCMV-immune (panels B and D) mice. To visualize the data, we use different scales on the plots. If
CD8+T cells were to affect the frequency of peptide-pulsed targets, a negative correlation between the
ratio R and CD8+T cells would be expected. However, especially in acutely infected mice (panels A
and C), there often are positive correlations between this ratio and the frequency of peptide-specific
CD8+T cells.
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Figure S4: Changes in the ratio of the frequency of peptide-pulsed to unpulsed targets in the mouse
spleen as predicted by the mathematical model (given in eqn. (1)-(2)) with different killing terms
(given in eqn. (A.10) – (A.13)). The death rate of peptide-pulsed targets saturates with the frequency
of peptide-specific CD8+T cells (panel A), decreases with the frequency of target cells (panel B) or
saturates on the effector to target ratio (panel C). We solve the mathematical model analytically
(panel A) or numerically (panels B-C) with the following parameters: SB(0) = TB(0) = 5 × 10
6,
S(0) = T (0) = 0, δ = 0.001 min−1, σ = 0.001 min−1, ǫ = 0.005 min−1, k = 5 min−1, E = 0.05 (see
also Table 1). The frequency of targets in the spleen is calculated as T = T (t)/Ns where Ns = 8×10
7
is the number of splenocytes. In all panels, solid lines (with cE = cT = 0) predict changes in the ratio
R if killing follows the law of mass-action, i.e., K = kE.
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Figure S5: Changes in the ratio of the frequency of peptide-pulsed to unpulsed targets in the mouse
spleen as predicted by the mathematical model (given in eqn. (2)) for different frequencies of GP33-
specific effectors in the spleen (shown as f). The death rate of peptide-pulsed targets K is proportional
to the frequency of GP33-specific CD8+T cells, K = kf , with k = 2.1 min−1 as estimated from the
adoptive transfer experiments. Other parameters are α = 2.07 × 10−11 min−1, Ns = 7.7 × 10
8,
ǫ = 1.15× 10−3 min−1, and δ = 10−2 min−1. There is a small difference in the percent targets killed
between 106 and 2× 106 (and between 107 and 2× 107) effectors transferred.
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Figure S6: The observed correlation between the ratio of the frequency of GP33-pulsed and unpulsed
targets and the frequency of GP33-specific CD8+T cells in the spleen at different time points after
transfer in the adoptive transfer experiments. Data are structured by the time since the transfer of
target cells (shown in hours). Lines show linear regressions. Note that there is a relatively small
variation in th measured frequency of epitope-specific CD8+T cells.
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